chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This a a cluster of 5 unidentified patients' who experienced similar adverse events following vaccination with ADACEL. Initial report received from a health care professional on 17 May 2011. A group of 5 unidentified patients' received on unknown dates an intramuscular injection (sites not reported) of ADACEL, sanofi pasteur Ltd. lot number C3823 and sanofi pasteur Inc. lot number U3874CA. The patient's developed 5-7 days after vaccination red, raised welt about the size of a half dollar at the injection site which was warm and tender to touch, painful and itchy. The patient's also had rashes, hives and swelling. The vaccinations were given over the last two weeks. The patient's required a doctor's visit. The outcomes were reported as unknown. Documents held by sender: None.
vestibulitis; This spontaneous case was reported by a physician and describes the occurrence of VESTIBULITIS (vestibulitis) in a male patient of an unknown age who received mRNA-1273 (Spikevax) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced VESTIBULITIS (vestibulitis). At the time of the report, VESTIBULITIS (vestibulitis) outcome was unknown.        The action taken with mRNA-1273 (Spikevax) (Unknown) was unknown.   For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication were reported.   No treatment drug were reported.   This case was linked to MOD-2022-590554 (Patient Link).
Child received DTAP on 8/27/01 in right deltoid, IM, and returned to our office on 8/28/01 with a 3" X 3" redness, swelling and induration over his right deltoid area. He is not yet recovered; here today.
Site: Itching at Injection Site-Medium, Site: Redness at Injection Site-Medium, Systemic: Allergic: Itch Generalized-Medium, Systemic: Allergic: Rash Generalized-Mild, Additional Details: patient had itchiness and redness on arm after getting shot.  itching was not near the injection site, it was further down the arm. administered benadryl as soon as she mentioned it (~5 minutes after shot).  patient then said she was feeling fine 20 minutes later and left.  no issues with airway/face.  counseled her on what to do if symptoms return or if airway gets affected.
Waves of exhaustion for 5-6 days and discomfort at injection site for 6 days following injection. When the exhaustion would hit, starting the day after injection, I was too weak to go up and down stairs. It seemed significant and was more than normal tiredness, and I ended up needing to take a half day at work four days after vaccination. On the sixth day after vaccination, I was feeling well again and discomfort at the injection site had subsided as well.  It was the worst the day after getting vaccinated, which was to be expected. I did not expect it to last so long.
Bilateral pulmonary embolism; Deep Vein Thrombosis in lower left leg; This is a spontaneous report from a contactable consumer (patient).   A 68-year-old male patient received bnt162b2 (BNT162B2), dose 2 via an unspecified route of administration, administered in Arm Right on 19Mar2021 09:30 (Lot Number: EN6204) at the age of 68 years old as DOSE 2, SINGLE for covid-19 immunisation. The patient received the first dose of BNT162B2 on 26Feb2021 at 10:00 AM  Lot number EN6200 at Right arm at the age of 68 years old for Covid-19 Immunisation. Medical history included ongoing hypertension from an unknown date. No known Allergies. Concomitant medications included propranolol (PROPRANOLOL); calcium (CALCIUM); krill oil (KRILL OIL) and unspecified multivitamin all taken for an unspecified indication, start and stop date were not reported.  The patient experienced bilateral pulmonary embolism and deep vein thrombosis in lower left leg on 23Jun2021 12:00 with outcome of recovering.  The events resulted in: [Doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care, Hospitalization for 4 days, Life threatening illness (immediate risk of death from the event)]. The patient received tPA and Heparin therapy as treatment. The patient underwent lab tests and procedures which included Nasal Swab: negative on 26Jun2021 Nasal Swab.
Information has been received from a licensed practical nurse, concerning a 72 year old female with hypertension, chronic obstructive pulmonary disease, hypothyroidism, ATIVAN and penicillin allergy and with a history of lung cancer, who on 03-MAR-2009 was vaccinated with PNEUMOVAX 23 (659922/1667U), 0.5 ml, intramuscularly. Concomitant therapy included unspecified blood pressure medication, BENADRYL, montelukast sodium (MSD), and SYNTHROID. The licensed practical nurse reported that on 04-MAR-2009, the patient experienced pain, redness and swelling in her arm the day after receiving the vaccination. It was noted that the reaction occurred in the general area of the injection site. The patient was treated with antibiotic. The patient had previously received an unspecified number of PNEUMOVAX 23. The patient recovered on an unspecified date. The patient sought medical attention and was seen at the nurse's practice. Follow-up information was received from the licensed practical nurse indicating that the patient was a 72 year old female patient weighing 117 pounds and 61.5 inches in height, with penicillin allergy, who on 03-Mar-2009 at 11:30 AM was vaccinated with the fourth dose of PNEUMOVAX 23 (659922/1667U), intramuscularly in the left deltoid. It was reported that the patient was not acutely ill at the vaccination visit. The reporter stated that on 04-MAR-2009 at 11:00 AM, the patient was given cephalexin 500mg. It was reported that the patient was offered an ultrasound of area but she declined. At the time of report, the patient was still complaining of pain in arm. Pain around injection site, injection site red and swollen were considered to be another important medical event by the licensed practical nurse. Additional information is not expected.
dx'd with COVID 8/29/21, admitted to hospital, dc'd to home on 8/31/21; sent per Home Health nurse to ED on 9/13/21 for chest pain, dyspnea, increased weakness past 2-3 dys; pt found to be hypoxic; placed on O2 OptiFlow 50/70; given diuretics, antibiotics, steroids; DNI/DNR; condition worsened and pt placed on OptiFlow 100%; inpatient hospice; comfort care measures; pt died in the hosp after condition continued to deteriorate
Day  following first Moderna vaccine, started getting a very itchy rash which covered much of upper half of back.  Looked more like  red blotches than smaller rash.  Just placed powder etc. on it myself for a few days until I saw  Doctor 2/2/2021 for previously scheduled wellness check.  Doctor prescribed a Prednisone pack ( 21 pills over six days) to address the itching/rash.
This spontaneous report as received from a licensed vocational nurse refers to a 4 year old female patient. Pertinent medical history, drug reactions or allergies were not reported. On 08-DEC-2010, the patient was vaccinated with VARIVAX (Merck) (dose, route and lot # were not reported). Concomitant medication was not reported. On 25-DEC-2013, the patient who previously received VARIVAX (Merck), subsequentially developed shingles. The patient was seen in a urgent care facility for treatment. The patient was treated with acyclovir. The patient's present status was reported as recovering. Causality was not reported. Additional information has been requested.
No additional adverse event; the patient was inadvertently administered a dose of ZOSTAVAX that was expired; This spontaneous report was received from a registered nurse who refers to a 62-year-old, female patient. No information regarding her medical history, concurrent conditions, concomitant medications, drug reactions or allergies was provided.  On 13-JUL-2020, the patient was inadvertently vaccinated with expired dose of zoster vaccine live (ZOSTAVAX), lot # S002390, expiration date was not provided but upon internal validation established as 22-APR-2020 (exact dose, strength, route of administration and anatomical location were not reported) for prophylaxis (expired product administered). No additional adverse event was reported.
I received my shot at 3:45 p.m.  A few hours after receiving my 1st Moderna shot in my right arm, it began throbbing (perhaps around 7 p.m.) At night, the throbbing in my arm was so severe that it woke me up several times (11 p.m., 2 a.m., and 4 a.m., at least) I awoke at 6:20 a.m. and began working; I immediately noticed that I was hot and had a mild fever and my lower back was hurting; arm was still throbbing. Within about 30 minutes of working on my computer, I began feeling nausea, the sweats/chills were more prevalent, and my arm still hurt.  I went and laid down in bed and fell asleep around 7:15 a.m. I woke up at 10 a.m. I still had a mild fever with sweats/chills, a headache, body aches (back and neck), and my arm was still sore Around 10:30 a.m. I took 3 Advil and ate, and felt a little better. As of 12:45 p.m. I just went on a sneezing binge and have a runny nose, my neck is still aching, arm is still throbbing, I still have a headache and my eyes feel heavy, and I still am getting chills/sweats.  I do not feel great.
patient felt dizzy and nauseous post vaccination. given ice packs and water. symptoms subsided within 5-10 min
Induration, swelling, redness, blistering over entire L deltoid area. 7/24 started on prelone, Augmentin.
patient stated that he noticed the rashes on the back and below his chest. He said He will go see his PCP on 5/6/2020.
Shingles; Spot that still itches not marks or sot; Spot-like rash; This case was reported by a consumer via interactive digital media and described the occurrence of shingles in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On 6th April 2020, the patient received the 1st dose of Shingrix. On an unknown date, less than a year after receiving Shingrix, the patient experienced shingles, localized itching and spot-like rash. On an unknown date, the outcome of the shingles, localized itching and spot-like rash were unknown.   It was unknown if the reporter considered the shingles, localized itching and spot-like rash to be related to Shingrix.  Additional details were as follows: The age at vaccination was not reported. Patient reported that after receiving Shingrix experienced shingles and asked about when its to get the shot again. Patient reported about still experiencing spot that still itches not marks or sot. The reporter did not consent to follow up. There was a discrepancy regarding capturing event shingles. Query had been raised to HUB, it was unknown whether the patient experienced shingles after the dose. In addition, it was unknown whether the patient had 1st dose but as per notes, it seems that this was the patient's 1st dose and yet to receive 2nd one
No immediate adverse effects.   Shot given at 10:30 am, Monday morning 04/12/21 At 3 am, 04/13/21, I woke up with very cold feet and yet was piled with blankets in bed. I could not warm up my feet.  I got out of bed to find I was, feverish, had chills, headache, and diarrhea
swelling of the skin near the site of the injection; Redness in her skin near injection site; Tendernes of the skin near the site of injection; This spontaneous case was reported by an other health care professional (subsequently medically confirmed) and describes the occurrence of VACCINATION SITE SWELLING (swelling of the skin near the site of the injection), VACCINATION SITE ERYTHEMA (Redness in her skin near injection site) and VACCINATION SITE PAIN (Tendernes of the skin near the site of injection) in a 48-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No reported medical history.). Concomitant products included ORAL CONTRACEPTIVE NOS for Birth control pill.    On 28-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Jan-2021, the patient experienced VACCINATION SITE SWELLING (swelling of the skin near the site of the injection), VACCINATION SITE ERYTHEMA (Redness in her skin near injection site) and VACCINATION SITE PAIN (Tendernes of the skin near the site of injection). At the time of the report, VACCINATION SITE SWELLING (swelling of the skin near the site of the injection), VACCINATION SITE ERYTHEMA (Redness in her skin near injection site) and VACCINATION SITE PAIN (Tendernes of the skin near the site of injection) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment information was not provided.   Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Developed skin rash on arms, neck, face, and torso. Developed hives on eyelids. Fatigue, and fever accompanied. Symptoms were noticeable around 5 hours after administration of 1st dose of Pfizer vaccine.
Suffered from the RA; Has a hard time sleeping at night; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP).  A 68-year-old male patient received BNT162b2 (BNT162B2), on 20Sep2021 as dose 1, single (Batch/Lot number: unknown) at the age of 68 years for covid-19 immunisation. The patient's relevant medical history included: "Guillain-Barre syndrome" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: INSOMNIA (non-serious) with onset 2021, outcome "recovered" (2021), described as "Has a hard time sleeping at night"; RHEUMATOID ARTHRITIS (medically significant) with onset 2021, outcome "recovered" (2021), described as "Suffered from the RA". Therapeutic measures were taken as a result of rheumatoid arthritis. Therapeutic measures were not taken as a result of insomnia. Clinical course: His arthritis was really bad due to having to temporarily stop the medication to get a COVID vaccine and he also has a hard time sleeping at night. As per directed by Pfizer, Patient was told to not to take med for 1 (one) week before Pfizer each injection. Because of my earlier Guillain-Barre syndrome. My first injection was on 20Sep2021 and the second on 17Oct2021. Not taking the med but for 1 week I suffered from the RA. Till nearly the end of year. The Xeljanz XR did its job and the patient feels great again.   The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202101655837 same patient/event, different vaccine dose;
Immediate dizziness, flushed sensation, itchy throat and lips, tachycardia, and high blood pressure
This medically confirmed spontaneous report (initial receipt 19-Oct-2015) concerns a patient (unknown demographics) who was not pregnant and required a rescue inhaler "once in a blue moon". On 16-Oct-2015, the patient received Afluria (Influenza virus vaccine polyvalent, batch number U55106) 0.5mL via the intramuscular route for the prevention of influenza. On 16-Oct-2015, the patient developed respiratory distress after receiving Afluria. 12 hours after receiving the vaccine, the patient had difficulty breathing and required a PRN (when required) albuterol nebulizer treatment and a rescue inhaler. This treatment helped the patient, in which the symptoms resolved in less than 24 hours. The outcome was recovered. Reporter's Comments: Reporter's comments: The reporter considered the events related to Afluria. Sender's Comments: Company comments: Seriousness: Serious. Medically significant. Listedness: Unlisted. Assessment according to the CCDS for CSL Inactivated Influenza Virus Vaccine and the Afluria PI, respiratory distress is unlisted. Causality: Possible. Time to onset is same day of vaccination. Past history of suspected asthma as patient required inhaler occasionally. Respiratory symptoms responded to and resolved with nebulised bronchodilator within 24 hours is suggestive of asthma exacerbation which is plausible following vaccination.  Influenza vaccination causally attributable due to temporal association and no other triggers specified.
Received Pfizer bivalent on 9/20/22 at 10:45am.  On 9/21/22 at 8:10am resident developed a fever, lethargy, and vomiting. V/S 141/77 P-109, R-33, T-101.7, Spo2-86% on room air.  O2 was started at 3L/min.  911 was notified and resident transferred to a Hospital ER locally.  Was admitted to the hospital with diagnosis of intractable vomiting with aspiration resulting in aspiration pneumonia.  Dr. states pt. has prior history of similar reaction to last booster and I feed the adverse reaction are related to the bivalent booster.  Order was received at the HCF for resident to not received any further Covid-19 immunizations.
Seen in ER for episode of hypothermia day after influenza vaccine. Had rectal temperature of 96 after waking from nap w/ associated acrocyanosis. Mother noted decreased appetite, slight nasal congestion as well. Was well appearing + with normal temperature in ER (by the time was seeN)
Mother stated that pt received shots on Monday (11/15/10) & this AM (11/17/10) she noticed redness & hardness to (L) arm (Deltoid) & warm to touch.
Pt received 1st Moderna COVID-19 vaccine on 2/13/21.  Starting on 2/16/21, pt developed tinnitus, which has persisted since that time.
1/2 hr p/recvd MMR/HIB pt had tiny bumps on eyelids, cheek & arms; no itching or breathing problems; pt given DPH & was sleeping in 30mins w/easy resp; bumps turned into welts;
Shingles; Painful; Miserable; sick; rash; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of shingles in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Co-suspect products included COVID-19 VACCINE for prophylaxis.   The patient's past medical history included shingles (had them many times).   On an unknown date, the patient received Shingles vaccine and COVID-19 VACCINE. On an unknown date, 3 days after receiving Shingles vaccine and an unknown time after receiving COVID-19 VACCINE, the patient experienced shingles (Verbatim: Shingles), pain (Verbatim: Painful), feeling bad (Verbatim: Miserable), sickness (Verbatim: sick) and rash (Verbatim: rash). The outcome of the shingles, pain, feeling bad, sickness and rash were not reported.   It was unknown if the reporter considered the shingles, pain, feeling bad, sickness and rash to be related to Shingles vaccine.  It was unknown if the company considered the shingles, pain, feeling bad, sickness and rash to be related to Shingles vaccine.   Additional Information: GSK Receipt Date: 10-MAR-2023 This case was reported by a patient via (social media) interactive digital media. The patient reported that it was miserable and painful. The patient had shingles many times.  The patient had the Covid and Shingles vaccine on same day last year and three days later he got shingles.  The patient was sick three days before the rash appeared. The patient said he/she could not ever have two shots of anything on the same day, per doctor. If one compromised, it worth the risk just not on the same day. It was unknown if the reporter considered the shingles, pain, feeling bad, sickness and rash to be related to COVID 19 vaccine. Less than a week after receiving Shingles vaccine and COVID-19 VACCINE, the patient experienced sickness and rash. Follow-up would not possible as no contact details were available
11 - 19 days post vax, the patient was diagnosed with arthritis. Unspecified medical attention was sought.
i had a headache that lasted about 6 days. i also had muscle aches which lasted 2 days.
Initial unsolicited report received from a health care professional on 16-Jan-2018. This case involves a 47-year-old male patient who was vaccinated with a 0.5 ml dose of ADACEL injection once (batch number- U5810AA, expiration date, dose in series and site of administration were not reported), via intramuscular route on 12-Jan-2018. The patient medical history and concomitant medications were not reported. Also reported that the patient had no known drug allergies (NKDA) and chronic illness. On 13-Jan-2018, one day after the vaccination, the patient experienced bumps on both sides of his tongue while woke up. Laboratory data and corrective treatment were not reported. The outcome of the event was not recovered. List of documents held by sender: none.
Prior to the vaccination I did not have HBP. Several weeks after vaccination, around 03/01/2021, I was going to routine doctor appointment and I notice my BP was suddenly high.  The BP was up and down for a month and a half after the vaccine. My blood pressure was very high 160/98.  I went to see a Cardiologist and he immediately said I had HBP and put me on medication. He sent me for a bunch of test.  My BP was spiking up and down. I thought it was white coat syndrome or the tightness of the cuff.  I did not want to take my HBP medication. I was afraid to take the medication when my BP was very low. I did not know what was going on. The doctor suggested I track my BP for two weeks. The results were suggested I did not have HBP. After I had the 3rd booster vaccine, a couple of weeks later I had the same HBP results again-190/105. It was worse after the 3rd dose, instead of spiking up and down. It was spiking up.  I have a heart murmur that I did not have before.
On 12/22/03, patient was bitten at the base of the right fourth finger(palmar side) by racoon who had been fighting with the patient's dogs.  Patient seen in ER on 12/22/03.  Rigorous wound scrubbing with H2O2 followed by tetanus shot(left deltoid)and initiation of day 1 rabies post exposure prophylaxis: rabies immunoglobulin 20 units per kg IM(4 cc RIG at wound site and 15 cc IM divided into 3 injections (right and left gluteals and right deltoid)and rabies vaccine (first of 5 doses).  Also medicated with Keflex 500 mg po.  Patient completed the course of post exposure prophylaxis on the 3rd, 7th, 14th, and 28th days. Last rabies vaccine given on 01/22/04. On 02/04/04, patient admitted to hospital by Dr. for evaluation of neurological symptoms.  Patient presented with muscle pain at the injection sites, followed by joint pains and some weakness, mainly limited to hands and feet, with numbness.  Also has continuing diarrhea.  Patient also complaining of heart palpitations.  Transferred on Feb. 5th for continued evaluation.   Labs detailed in block 12 and all ER notes and documentation, consultation faxed. Discharge summary states serum sickness, nausea, vomiting, dehydration, dizziness. msv
10 days after my vaccination, the cornea transplant I had done it my right eye was rejected. My ophthalmologist and I believe there is a correlation between the vaccine and my cornea rejection incident since vaccines fight foreign matter in the body and the transplant is a foreign material.  In addition, the cornea had be perfectly accepted for 4.5 years and only got rejected after the vaccine.  This is only a suspected adverse reaction but seems to be the most likely cause for the rejection.  We are treating it with large doses of steroid drops.  After one week of the drops there appears to be no improvement.  If there is no improvement over the next week we are considering surgery to redo the transplant with a new cornea.